Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells

Cancer Research

Volumn 57, Issue 13, 1997, Pages 2606-2610

  Guvakova, Marina A ^a   Surmacz, Ewa ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; COLLAGEN; ESTROGEN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; CYTOSTASIS; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL DIVISION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MITOGEN-ACTIVATED PROTEIN KINASE 1; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEINS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0030849605     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lee, A. V., and Yee, D. Insulin-like growth factors and breast cancer. Biomed. Pharmacother., 49: 415-421, 1995.
2. Papa, V., Gliozzo, B., Clark, G. M., McGuire, W. L., Moore, D., Fujita-Yamaguchi, Y., Vigneri, R., Goldfine, I. D., and Pezzino, V. Insulin-like growth factor I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res., 53: 3735-3740, 1993.
3. Peyrat, J. P., and Bonneterre, J. Type 1 IGF receptor in human breast diseases. Breast Cancer Res. Treat., 22: 59-68, 1992.
4. Rocha, R. L., Hilsenbeck, S. G., Jackson, J. G., and Yee, D. Insulin-like growth factor binding protein-3 (IGFBP3) and insulin receptor substrate (IRS1) in primary breast cancer: larger tumors have higher BP3 levels and higher levels of IRS-1 are associated with lower disease-free survival (DFS) rate. Breast Cancer Res. Treat. 37(Suppl.): 55, 1995.
5. Surmacz, E., and Burgaud, J-L. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin. Cancer Res., 1: 1429-1436, 1995.
6. Guvakova, M. A., and Surmacz, E. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp. Cell. Res., 149-162, 1997.
7. Cullen, K. J., Lippman, M. E., Chow, D., Hill, S., Rosen, N., and Zwiebel, J. A. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol. Endocrinol., 6: 91-100, 1992.
8. Neuenschwander, S., Roberts, C. T., Jr., and LeRoith, D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology, 136: 4298-42303, 1995.
9. Rubin, R., and Baserga, R. Biology of disease. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis and tumorigenicity. Lab. Invest., 73: 311-331, 1995.
10. Argetsinger, L. S., Hsu, G. W., Myers, M. G., Billestrup, N., White, M. F., and Carler-Su, C. Growth hormone, interferon-γ, and leukemia inhibitory factor promoted tyrosyl phosphorylation of IRS-1. J. Biol. Chem., 270: 14685-14692, 1995.
11. Vuori, K., and Ruoslahti, E. Association of insulin receptor substrate-1 with integrins. Science (Washington DC), 266: 1576-1578, 1994.
12. Pelicci, G., Lanfrancone, E., Salcini, A. E., Romano, A., Mele, S., Borrello, M. G., Segatto, O., Di Fiore, P. P., and Pelicci, P. G. Constitutive phosphorylation of Shc proteins in human cancers. Oncogene, 11: 899-907, 1995.
13. Habib, T., Herrera, R., and Decker, S. J. Activators of protein kinase C stimulate association of Shc and the PEST tyrosine phosphatase. J. Biol. Chem., 269: 25243-25246, 1994.
14. Jordan, C. V. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res. Treat., 31: 41-52, 1994.
15. de Cupis, A., Noonan, D., Pirani, P., Ferrera, A., Clerico, L., and Favoni, R. E. Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol-and IGF-I-induced proliferation of human breast cancer-derived cells. Br. J. Pharmacol., 116: 2391-2400, 1995.
16. Huff, K. K., Knabbe, C., Linsey, R., Kaufman, D., Bronzert, D., Lippman, M. E., and Dickson, R. B. Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 cells. Mol. Endocrinol., 2: 200-208, 1988.
17. Colletti, R. B., Roberts, J. D., Devlin, J. T., and Copeland, K. C. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res., 49: 1882-1884, 1989.
18. Freiss, G., Rochefort, H., and Vignon, F. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity. Biochem. Biophys. Res. Commun., 173: 919-926, 1990.
19. Kawamura, I., Lacey, E., Mizota, T., Tsuimoto, S., Nishigaki, F., Manda, T., and Shimomura, K. The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells. Anticancer Res., 14: 427-432, 1994.
20. Yamasaki, H., Prager, D., Gebremedhin, S., and Melmed, S. Insulin-like growth factor-I (IGF-I) attenuation of growth hormone is enhanced by overexpression of pituitary IGF-I receptors. Mol. Endocrinol., 5: 890-896, 1991.
21. Doerr, M., and Jones, J. The roles of integrins and extracellular matrix proteins in the IGF-I-stimulaled chemotaxis of human breast cancer cells. J. Biol. Chem., 271: 2443-2447, 1996.
22. Kleinman, D., Karas, M., Roberts, C. T., Jr., LeRoith, D., Phillip, M., Segev, Y., Levy, J., and Sharoni, Y. Modulation of insulin-like growth factor I receptors and membrane-associated IGF-I binding proteins in endometrial cancer cells by estradiol. Endocrinology, 136: 2531-2537, 1995.
23. Kleinman, D., Karas, M., Danilenko, M., Arbeli, A., Roberts, C. T., Jr., LeRoith, D., Levy, J., and Sharoni, Y. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology, 137: 1089-1095, 1996.
24. Clark, J. W., Santos-Moore, A., Stevenson, L. E., and Frackelton, A. R., Jr. Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway. Int. J. Cancer, 65: 186-191, 1996.
25. Vinkvanwijngaarden, T., Pols, H. A. P., Buurman, C. J., Birkenhager, J. C., and Vanleeuwen, J. P. T. M. Inhibition of insulin-and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D-3 and the vitamin D-3 analogue EB 1089. Eur. J. Cancer, 32A: 842-848, 1996.
26. Freiss, G., and Vignon, F. Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Mol. Endocrinol., 8: 1389-1396, 1994.